Posters

Association of urinary 11-dehydro-thromboxane B2 levels in smoking, smoking cessation and Tobacco Heating System use

Gonzalez Zuloeta, A.; Pouly, S.; de La Bourdonnaye, G.; Baker, G.; Luedicke, F.

Conference date
Jun 27, 2014
Conference name
Society for Epidemiologic Research (SER) 2014
Link to more information
Topic
Summary

Smoking has been associated with cardiovascular disease and there is evidence that this might be mediated by the increased production of thromboxane. Whether metabolites of thromboxane, such as 11-dehydro-thromboxane B2 (TXB2), could be used as a biomarker of risk in the assessment of candidate modified risk tobacco products (MRTPS) is not clear. The aim of this literature review and meta-analysis (MA) was to determine the association of smoking status and TXB2 levels. Additionally we evaluated the effect of smoking cessation and the use of a tobacco heated system (THS) currently in development, to urinary levels of 11-dehydro-thromboxane B2. 

Related Publications

Evaluating Use Patterns of a Closed Electronic Nicotine Delivery System Among Adults in the United States Who Smoke Cigarettes Daily: 8-Week Actual Use Study

Perception and Behavior

Barriers to stop smoking (BASS): Results and insights from four years of empirical research in Germany

Perception and Behavior

Unlocking a decade of tobacco heating system post-market surveillance

Post-Market Studies and Surveillance Study

Reasons for oral nicotine product use among adults who smoke or use smoke-free products in Germany - Results from the Barrier to Stopping smoking (BASS) survey

Perception and Behavior

Misunderstanding nicotine delivery: Discussion on nicotine pouches

Nicotine

AeroSolved: Wall Boundary Conditions for Liquid Multispecies Aerosol Deposition at Transient and High-Humidity Flows

Aerosol Physics

PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
​
Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.